Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $2.0 million.

  • Xeris Biopharma Holdings' Change in Account Payables rose 2075.02% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6 million, marking a year-over-year increase of 2496.33%. This contributed to the annual value of -$9.6 million for FY2024, which is 23813.77% down from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Change in Account Payables stood at $2.0 million, which was up 2075.02% from -$4.4 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Change in Account Payables registered a high of $6.9 million during Q1 2023, and its lowest value of -$5.2 million during Q4 2024.
  • Over the past 5 years, Xeris Biopharma Holdings' median Change in Account Payables value was $297000.0 (recorded in 2023), while the average stood at $9684.2.
  • Over the last 5 years, Xeris Biopharma Holdings' Change in Account Payables had its largest YoY gain of 45656.57% in 2024, and its largest YoY loss of 209000.0% in 2024.
  • Xeris Biopharma Holdings' Change in Account Payables (Quarter) stood at $4.4 million in 2021, then tumbled by 84.15% to $690000.0 in 2022, then crashed by 151.16% to -$353000.0 in 2023, then plummeted by 1373.94% to -$5.2 million in 2024, then skyrocketed by 138.36% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, -$4.4 million for Q2 2025, and $4.1 million during Q1 2025.